Antagonist protocols: Residual LH levels and the interest of exogenous LH supplementation;Protocoles antagonistes: Taux résiduel de LH et intérêt d'une supplémentation en LH exogène

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 33, Issue 6 II, 2004, Pages

  Cedrin Durnerin I ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

Assisted reproductive technology; GnRH antagonists; Ovarian stimulation; Recombination LH

Indexed keywords

CETRORELIX; ESTRADIOL; FOLLITROPIN; GANIRELIX; GONADORELIN ANTAGONIST; LEVONORGESTREL; LUTEINIZING HORMONE; RECOMBINANT LUTEINIZING HORMONE;

FEMALE; FOLLICULAR PHASE; HORMONE SUBSTITUTION; HUMAN; INFERTILITY THERAPY; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; OOCYTE; PREGNANCY RATE; REVIEW; STEROIDOGENESIS;

ADULT; ANOVULATION; BIOLOGICAL AVAILABILITY; CLINICAL PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG THERAPY, COMBINATION; ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEVONORGESTREL; LUTEINIZING HORMONE; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; PROSPECTIVE STUDIES;

EID: 5644255772     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (7)

1. The ganirelix dose-finding study group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod 1998; 13: 3023-31.
2. Albano C, Smitz J, Camus M, Riethmuller-Winzen H, Van Steirteghem A, Devroey P. Comparison of different doses of gonadotropin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 1997; 67: 917-22.
3. Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R. The use of a GnRH antagonist (cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Hum Reprod 1998; 13: 2411-4.
4. Olivennes F, Diedrich K, Frydman R, Felberbaum RE, Howles CM; Cetrotide Multiple Dose International Study Group; Cetrotide Single Dose International Study Group. Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences. Reprod Biomed Online 2003; 6: 432-8.
5. Lindheim SR, Morales AJ. GnRH antagonists followed by a decline in serum estradiol results in adverse outcomes in donor oocyte cycles. Hum Reprod 2003; 18: 2048-51.
6. Aboulghar MA, Mansour RT, Serour GI, Al-Inany HG, Amin YM, Aboulghar MM. Increasing the dose of human menopausal gonadotrophins on day of GnRH antagonist administration: randomized controlled trial. Reprod Biomed Online 2004; 8: 524-7.
7. Cédrin-Durnerin I, Grange-Dujardin D, Laffy A, Parneix I, Massin N, Galey J, Theron L, Wolf JP, Conord C, Clement P, Jayot S, Hugues JN. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2004; 19: 1979-84.